A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06047457` - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults	Phase 3
Completed	`NCT02569853` - DFN-11 Injection in Episodic Migraine With or Without Aura	Phase 3
Completed	`NCT00719134` - The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache	Phase 4
Completed	`NCT03700320` - Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine	Phase 3
Terminated	`NCT04936061` - Transnasal Cooling for Migraine	N/A
Recruiting	`NCT05042037` - Probiotics as Adjunctive Migraine Prophylaxis	N/A
Recruiting	`NCT05281770` - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Recruiting	`NCT04628429` - CGRP Inhibition, Autonomic Function, and Migraine
Active, not recruiting	`NCT05028569` - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine	Phase 3
Withdrawn	`NCT01257893` - Aspirin Resistance in Women With Migraine	N/A
Recruiting	`NCT06051604` - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine	N/A
Completed	`NCT03132233` - Energy for the Brain	N/A
Completed	`NCT03939312` - Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine	Phase 3
Completed	`NCT03927144` - Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients	Phase 4
Recruiting	`NCT06248671` - Prophylactic Treatment With Atorvastatin for Episodic Migraine.	Phase 2
Recruiting	`NCT05711394` - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine	Phase 3
Recruiting	`NCT05449145` - The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine	N/A
Completed	`NCT04031781` - The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis	N/A
Completed	`NCT05264129` - Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine	Phase 4
Completed	`NCT04740827` - Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.	Phase 3

NCT number	NCT03963232
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 3
Start date	July 30, 2019
Completion date	March 11, 2022

A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine — PERSIST

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms